What pulmonologists think about the asthma–COPD overlap syndrome

Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma–COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity ,0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids

La neumonía adquirida en la comunidad de los ancianos: diferencias entre los que viven en residencias y en domicilios particulares

Objetivo: La neumonía adquirida en la comunidad (NAC) de los ancianos que viven en una residencia se considera distinta del resto en cuanto a etiología, forma de presentación y pronóstico. Sin embargo, existen pocos estudios en nuestro país que confirmen estos aspectos, sin olvidar las diferencias etiológicas regionales de las NAC. Pacientes y métodos: Se ha realizado un estudio prospectivo de 18 meses de duración (2002-2003), en el que se ha incluido a todos los pacientes mayores de 65 años que ingresaron por NAC en nuestro hospital. Se recogieron las características clínicas, analíticas y radiológicas haciendo especial hincapié en la situación funcional --­escala del Eastern Cooperative Oncology Group (ECOG), índices de Barthel y Karnofsky--­ y en la comorbilidad. Para el diagnóstico etiológico se realizaron 2 hemocultivos, antígeno de Legionella en orina y serología de gérmenes atípicos; en los casos indicados también se practicó cultivo bacteriológico de muestras respiratorias. Resultados: Se incluyó a 91 pacientes, de ellos 25 procedían de residencias. Estos últimos tenían mayor edad (82 ± 4 frente a 73 ± 5 años; p = 0,0001), mayor comorbilidad global (p = 0,0001) --como enfermedades aisladas eran significativamente más comunes la diabetes mellitus, la enfermedad cerebrovascular, la insuficiencia cardíaca congestiva crónica y la demencia-- y peor estado funcional (ECOG: 2,09 ± 0,9 frente a 0,93 ± 1,1, p = 0,001; índice de Barthel: 19 ± 33 frente a 77 ± 35, p = 0,001; índice de Karnofsky: 51 ± 17 frente a 78 ± 23, p = 0,001). En cuanto a las características clínicas, encontramos diferencias significativas en la frecuencia respiratoria (39 ± 11 frente a 27 ± 7 respiraciones/min; p = 0,001), la presión arterial diastólica (69,5 ± 20 frente a 79,2 ± 18 mmHg; p = 0,029) y en la temperatura (36,6 ± 1,2 frente a 37,7 ± 1,1 °C; p = 0,001). En la radiografía de tórax, la NAC de residencia presentó mayor número de lóbulos afectados (p = 0,004). Además, estos pacientes tenían mayor hipoxemia, acidosis, anemia, hipoalbuminemia y elevación de las cifras de urea y creatinina. Asimismo, la puntuación en la escala de Fine fue superior (134 ± 26 frente a 95 ± 28; p = 0,001) y presentaron mayor mortalidad (7/25 frente a 3/66; p = 0,005). En la mayoría de los pacientes no se pudo encontrar un diagnóstico etiológico, pero no se observaron diferencias significativas entre ambos grupos. La variable predictora de mortalidad de los ancianos de la serie --modelo de regresión (pasos sucesivos)-- fue la urea (R2 corregida = 0,452). Conclusiones: En nuestra población, los ancianos que viven en residencias tienen mayor edad, pluripatología e importante deterioro funcional. En estas circunstancias la NAC adquiere especial gravedad y es una causa importante de mortalidad, pese a que los agentes etiológicos no parecen diferir de los habituales

What pulmonologists think about the asthma–COPD overlap syndrome

Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma–COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity ,0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids